探讨淋巴结直径对超声引导微波消融（MWA）治疗甲状腺癌颈部转移淋巴结（CMLN）疗效和安全性的影响。共32例甲状腺癌患者58个CMLN接受超声检查-指导MWA并被纳入回顾性研究。根据CMLN的平均最大直径将患者分为三组：A组（直径≤10mm）、B组（10mm<直径≤20mm）和C组（直径>20mm）。该研究比较了三组患者微波消融前后颈部转移淋巴结和血清甲状腺球蛋白（sTg）水平的变化以及并发症的发生率。这项研究的技术成功率为100%（32/ 32)，他们没有表现出严重的并发症。与 MWA 之前的测量结果相比，所有三个患者组的最后一次随访时 CMLN 的平均最大直径和体积以及 sTg 水平均显着降低 (p <0.05)。与C组相比，A组和B组的淋巴结缩小率和完全消失率较高。但三组的复发率依次为：C组>B组>A组。轻度并发症发生率A组>C组>B组。MWA是治疗CMLN安全有效的方法，对于局部淋巴结有优势，但对于较大淋巴结有局限性。根据综合证据评估，建议仔细考虑并制定个性化计划。版权所有 © 2024 肖、陈、李、李和朱。

To explore the impact of lymph node diameter on the efficacy and safety of ultrasound-guided microwave ablation (MWA) in the treatment of cervical metastatic lymph nodes (CMLNs) from thyroid cancer.A total of 32 patients with 58 CMLNs from thyroid cancer underwent ultrasound-guided MWA and were included in the retrospective study. Patients were divided into three groups based on the mean largest diameter of the CMLNs: Group A (diameter ≤10mm), Group B (10mm < diameter ≤20mm), and Group C (diameter >20mm). The research involved comparing changes in cervical metastatic lymph nodes and serum thyroglobulin (sTg) levels, as well as the incidence of complications, before and after microwave ablation across three groups of patients.The technical success rate of this study was 100% (32/32), and they showed no major complications. Compared with measurements taken before MWA, the mean largest diameter and volume of CMLNs, as well as the sTg level, showed significant reductions (p <0.05) at the last follow-up in all three patient groups. Group A and B exhibited higher lymph node volume reduction rates and complete disappearance rates compared to Group C. However, the recurrence rate in the three groups were in the following order: Group C > Group B > Group A. The occurrence rate of mild complications was Group A > Group C > Group B.MWA is a safe and effective method for treating CMLNs, with advantages for localized nodes but limitations for larger ones. Careful consideration and personalized plans are advised, based on comprehensive evidence assessment.Copyright © 2024 Xiao, Chen, Li, Li and Zhu.